A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 111.78
GOOG 516.35
MSFT 47.66
BAC 17.62
FB 79.88

Recently Added

GNCMA 13.50
NGL 28.63
DRIV 24.04
MRD 19.52
RCL 80.59

Gaining Speed

DRIV 24.04
NGL 28.63
MRD 19.52
RCL 80.59
GNCMA 13.50

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More




Get Alerted When News Hits On This Stock - FREE!